Physician profile
Scot Graham
NPI 1568445369
$4,076.21
in general payments reported to CMS, 2019-2025
33 companies · $805 in 2025
The $805 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $823 · 2021: $351 · 2022: $414 · 2023: $716 · 2024: $557 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.81 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $821.19 | 2019-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Coloplast Corp | $783.57 | 2019-2023 | Saffron |
| Astellas Pharma US INC | $401.50 | 2023-2025 | Veozah |
| Abbvie INC. | $261.16 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.54 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $217.13 | 2022-2025 | |
| Baxter Healthcare | $182.74 | 2019-2020 | |
| Exeltis, USA INC. | $152.53 | 2020-2025 | Slynd |
| Coopersurgical, INC. | $117.52 | 2019-2025 | Sos |
| Daiichi Sankyo INC. | $86.89 | 2023-2024 | Injectafer |
| Myriad Women'S Health, INC. | $85.46 | 2023 | Myrisk |
| Organon LLC | $65.85 | 2022-2025 | Nexplanon |
| Exact Sciences Corporation | $64.87 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $49.05 | 2022-2023 | |
| Gynesonics, INC. | $47.18 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $46.42 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $46.05 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $45.67 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $36.54 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $34.17 | 2019 | |
| Novo Nordisk INC | $33.63 | 2023-2024 | Wegovy |
| C. R. Bard, INC. & Subsidiaries | $33.31 | 2024 | Bd Onclarity |
| Caldera Medical, INC | $29.96 | 2022 | |
| Medtronic, INC. | $28.74 | 2024 | Ligasure |
| Merck Sharp & Dohme LLC | $27.27 | 2020 | |
| Davol INC. | $26.49 | 2025 | Arista |
| Amag Pharmaceuticals, INC. | $22.78 | 2019 | |
| Sanofi Pasteur INC. | $21.22 | 2019 | |
| Bausch Health US, LLC | $21.14 | 2020 | |
| Boston Scientific Corporation | $15.78 | 2019 | |
| Shield Therapeutics INC | $14.74 | 2023 | Accrufer |
| Minerva Surgical, INC | $13.52 | 2023 | |
| Channel Medsystems, INC. | $11.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scot Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.